Michael E. Trigg

Michael E. Trigg, MD, is a highly experienced professional in the field of hematology-oncology, currently serving as Senior Consultant in GPD Hematology-Oncology at PPD since August 2021 and as President and Managing Director of MET Development LLC since June 2017, where expertise in medical affairs focuses on CAR-T cell therapies and cellular therapies for hematology and oncology. Dr. Trigg has held key positions including Advisory Board Member at Medicevo, Group Medical Director at Janssen Pharmaceutical Companies, and Vice President at Worldwide Clinical Trials, contributing significantly to protocol development and clinical trial collaboration. Previously, Dr. Trigg served as Chief Medical Officer at Adaptive Phage Therapeutics and Oncology Scientific Advisor at Bristol Myers Squibb, along with extensive academic tenure as a Professor of Pediatrics at Thomas Jefferson University. Dr. Trigg's medical education includes an MD with distinction from The George Washington University and a BA in Biology and French from Trinity College-Hartford.